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Abstract
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with type 2 diabetes mellitus
(T2D). The comparative efficacy of individual SGLT2i remains unclear. We searched PubMed, www.clinicaltrials.gov and the
Cochrane Central Register of Controlled Trials for randomised controlled trials exploring the use of canagliflozin, dapagliflozin,
empagliflozin or ertugliflozin in patients with T2D. Comparators included placebo or any other active treatment. The primary
endpoint was all-cause mortality. Secondary endpoints were cardiovascular mortality and worsening heart failure (HF). Evidence
was synthesised using network meta-analysis (NMA). Sixty-four trials reporting on 74,874 patients were included. The overall
quality of evidence was high. When compared with placebo, empagliflozin and canagliflozin improved all three endpoints,
whereas dapagliflozin improved worsening HF. When compared with other SGLT2i, empagliflozin was superior for all-cause
and cardiovascular mortality reduction. Empagliflozin, canagliflozin and dapagliflozin had similar effects on improving wors-
ening HF. Ertugliflozin had no effect on any of the three endpoints investigated. Sensitivity analyses including extension periods
of trials or excluding studies with a treatment duration of < 52 weeks confirmed the main results. Similar results were obtained
when restricting mortality analyses to patients included in cardiovascular outcome trials (n = 38,719). Empagliflozin and
canagliflozin improved survival with empagliflozin being superior to the other SGLT2i. Empagliflozin, canagliflozin and
dapagliflozin had similar effects on improving worsening HF. Prospective head-to-head comparisons would be needed to confirm
these results.
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Introduction
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a
new class of oral anti-diabetic drugs (OAD) with a moderate
effect on glycaemic control and a low risk of hypoglycaemia
and weight gain [1, 2]. Current evidence suggests that SGLT2i
improve cardiovascular endpoints including all-cause mortal-
ity, cardiovascular mortality, heart failure (HF) and atheroscle-
rotic macrovascular events [3]. The magnitude of cardiovas-
cular risk reduction with SGLT2i, however, differed between
trials [3–6]. Furthermore, there is concern regarding the po-
tential cardiovascular safety of some OAD [7]. There is thus
remaining uncertainty about the comparative efficacy of indi-
vidual SGLT2i or whether a class effect can be assumed. To
date, there are no prospective or retrospective head-to-head
comparisons of individual SGLT2i. Given the required sample
size and associated costs, a comparative SGLT2i trial may
never be done. We therefore performed a network meta-
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analysis (NMA) of randomised controlled trials to compare
comprehensively the cardiovascular benefits of SGLT2i in
patients with type 2 diabetes mellitus (T2D).
Methods
NMA is an extension of pairwise meta-analysis in which mul-
tiple treatments are being compared using both direct compar-
isons of interventions within randomised controlled trials and
indirect comparisons across trials based on a common com-
parator. NMA has advantages over pairwise meta-analysis,
such as clarification of inconsistent outcomes from multiple
studies including multiple common comparators and indirect
effect calculation of missing direct comparisons between im-
portant treatments. Also, NMA can provide increased statisti-
cal power and cross-validation of the observed treatment ef-
fect of weak connections with reasonable network connectiv-
ity and sufficient sample sizes. This results in greater precision
of treatment effect estimates and the ability to rank all the
interventions in a coherent way.
We performed the present review following the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) extension statement for reporting systematic re-
views incorporating NMAs of health care interventions
[8–11]. The protocol of the NMAwas prospectively registered
at final registration ID at PROSPERO: CRD42020151112.
Identification and selection of studies
We searched electronic databases (PubMed, Cochrane Central
Register of Controlled Trials) and websites (www.
clinicaltrials.gov) up to August 12, 2019 for randomised
controlled trials investigating the use of canagliflozin,
dapagliflozin, empagliflozin or ertugliflozin in patients with
T2D. Details of the search strategy are provided in the
supplemental material. In addition, reviews and meta-
analyses of SGLT2i published in PubMed between 2017 and
2019 were screened for additional SGLT2i trials. Two re-
viewers independently screened citations against the follow-
ing predefined selection criteria.
Study design Prospective randomised controlled trials with
either parallel-group (all endpoints) or cross-over design
(worsening heart failure (HF) only) were included. There were
no restrictions regarding date of publication, language or sam-
ple size.
PopulationWe included studies evaluating adults (≥ 18 years)
with a diagnosis of T2D and treatment with SGLT2i for at
least 24 weeks. There were no restrictions regarding sex, race,
background diabetes treatment or dose of SGLT2i.
Interventions Treatment was with either canagliflozin,
dapagliflozin, empagliflozin or ertugliflozin for at least
24 weeks. This arbitrary limit of 24 weeks was chosen to
allow a potential survival benefit to become detectable against
the overall low short-term baseline mortality in diabetic co-
horts. Analyses were restricted to canagliflozin, dapagliflozin,
empagliflozin and ertugliflozin since these agents have been
approved by both the United States Food and Drug
Administration and the European Medicines Agency.
Comparators Placebo or standard medical care.
Outcomes Primary outcome was all-cause mortality.
Secondary outcomes included cardiovascular mortality and
worsening HF.
Data extraction and quality assessment
All relevant articles were independently reviewed by two in-
vestigators to assess the eligibility of the article and abstract
with standardised data abstraction forms, and disagreement
was resolved by a third investigator. For each trial included,
details were extracted on study design, patient characteristics,
interventions and outcomes. The quality of included trials was
assessed using the Cochrane Collaboration Criteria [12].
Statistical analyses
This NMA was conducted with Stata software 15.0
(StataCorp, College Station, TX, USA) using the network
family of commands [13, 14]. A random effects model was
applied. The NMAwas performed to obtain estimates for out-
comes of primary and secondary endpoints, presented as rel-
ative risks (RR) and 95% confidence intervals (CI) for binary
outcomes. The plot of a network of drugs was used as a visual
representation of the evidence base and offered a concise de-
scription of its characteristics. It consists of nodes representing
the drugs being compared and edges representing the avail-
able direct comparisons (comparisons evaluated in at least one
study) between pairs of drugs [14–16]. The quality of treat-
ment effect estimates was rated following the Grading of
Recommendations Assessment, Development and
Evaluation (GRADE) approach [17, 18]. In order to make
the rank of treatments, we used the surface under the cumula-
tive ranking probabilities (SUCRA)—a transformation of the
mean rank that accounts both for the location and the variance
of all relative treatment effects [19]. SUCRA values range
from 0 to 1.0. The higher the SUCRA value, and the closer
to 1.0, the higher the likelihood that a therapy is in the top rank
or one of the top ranks; the closer to 0 the SUCRA value, the
more likely that a therapy is in the bottom rank, or one of the
bottom ranks [20]. To check for a publication bias, we de-
signed a funnel plot [14]. Consistency of results was evaluated
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in each loop by calculation of an inconsistency factor and
statistical significance determined via z-test [16, 21].
For trials comprising a core period and an extension period,
results of the core period were considered in the main analy-
ses. To test the stability of the results, we performed a sensi-
tivity analysis by including the results of the extension periods
of the respective trials, provided that double-blind treatment
was continued unchanged during the extension period. If treat-
ment changed during the extension period of a trial, only re-
sults from the core period were considered. Additional sensi-
tivity analyses excluded studies with a high risk of bias, stud-
ies with a treatment duration < 52 weeks and those not de-
signed as cardiovascular outcome trials. Data on different dos-
ages of active treatments and/or comparators were pooled for
each study. Study arms including more than one active treat-
ment (= combination therapy) were excluded from endpoint
analyses. All p values were two-tailed with the statistical sig-
nificance arbitrarily set at < 0.05.
Results
Literature search
The search strategy yielded 73 eligible records reporting on 64
trials [4–6, 22–87]. For three trials (NCT02681094,
NCT02630706, NCT00736879), results were not published
in a peer-reviewed journal but open to public at www.
clinicaltrials.gov. Information on study design and results
were thus extracted from www.clinicaltrials.gov. The
flowchart of the study selection process is shown in eFig. 1.
Agreement between reviewers was excellent (κ = 0.935, 95%
CI 0.891–0.980).
No trials directly compared two different SGLT2i. A total
of 44 trials compared SGLT2i with placebo, and 18 trials
compared SGLT2i with other active treatments. Two trials
compared SGLT2i with both placebo and another active treat-
ment. Canagliflozin was studied in 14 trials (n = 22,220 pa-
tients), whereas dapagliflozin was studied in 30 trials (n =
31,863 patients). Thirteen trials including 15,716 patients in-
vestigated the use of empagliflozin, and seven trials studied
ertugliflozin (n = 5074 patients). The corresponding network
plots detailing active treatments and endpoints reported are
shown in Fig. 1a–c. All but one were multicentre, parallel-
group trials and the mean treatment duration of the core trials
was 40 weeks. Fifteen trials comprised a core period and an
Fig. 1 Network plots with respect to a all-cause mortality, b cardiovas-
cular mortality, and c worsening HF. Legend: CANA, canagliflozin;
DAPA, dapagliflozin; EMPA, empagliflozin; ERTU, ertugliflozin; EXE,
exenatide; GLIME, glimepiride; GLIP, glipizide; LINA, linagliptin;
MET, metformin; PLA, placebo; SAXA, saxagliptin; SITA, sitagliptin;
VILDA, vildagliptin. Nodes represent the interventions of interest and
edges represent available direct comparisons between pairs of interven-
tions. Nodes and edges are weighted according to the number of studies
including the respective interventions. Coloured edges are employed to
present the risk of bias for each direct comparison in the network, with
green, yellow and red colours being used to denote pairwise meta-
analyses of low, unclear and high risk of bias
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extension period, in which double-blind treatment was contin-
ued unchanged. The mean study duration including extension
periods was 52 weeks. In total, the 64 trials reported data from
74,874 patients. Of these, 3155 patients were randomised to a
combination treatment of more than one study drug and were
therefore excluded from endpoint analyses. Outcome data
were thus analysed from 71,719 patients. For study character-
istics of trials included in the present NMA, please refer to
Table 1.
Patient characteristics
Patients were on average between 52 and 69 years old and
baseline HbA1c varied between 7.2% and 9.3%. The majority
of patients had preserved renal function. The prevalence of
cardiovascular disease was reported in 15 trials and varied
between 26.1% and 100%, totalling 26,360 patients. A total
of 7534 patients from 14 trials was treatment-naïve, whereas
67,340 patients received background treatment for diabetes
with OADs and/or insulin. For details, please see eTable 1.
Risk of bias
The overall risk of bias was low.With respect to the individual
items of the risk of bias assessment (eFig. 2), the majority of
studies provided adequate random sequence generation with
good group balance at baseline. All-cause mortality could be
retrieved for all but one trial, whereas cardiovascular mortality
was reported in 46 (71.9%) trials (n = 59,168 patients). Data
on HF outcomes were available for 42,683 patients included
in 12 trials. There was no systematic association between type
or size of the trial or the publication date and any pattern of
missing endpoint information. The comparison adjusted fun-
nel plot for all-cause mortality (eFig. 3) was symmetrical,
suggesting the absence of small-study effects and publication
bias.
Outcomes
For all endpoints including the respective outcome numbers
per trial arm, please refer to eTable 2.
All-cause mortality
The predictive interval plot summarizing the relative mean
effects along with the impact of heterogeneity on the respec-
tive confidence interval (= the predictive interval) of each
(network) comparison is shown in Fig. 2. Canagliflozin,
dapagliflozin and empagliflozin all had a beneficial effect on
all-cause mortality compared with placebo. In head-to-head
comparisons, the analysis suggests that empagliflozin is supe-
rior to both canagliflozin and dapagliflozin. No other head-to-
head comparison of any pair of treatments (including non-
SGLT2 treatments) found a significant difference between
agents, though for most of these comparisons, the 95% CI
was wide. SUCRAvalues are presented in Table 2. The graph-
ical display of the ranking based on the SUCRA values is
shown in eFig. 4. The inconsistency within the respective
closed loops for each comparison was overall low (eFig. 5)
and did not reach statistical significance for any of the loops.
Cardiovascular mortality
The predictive interval plot (Fig. 3) showed that empagliflozin
was again superior to placebo, canagliflozin and dapagliflozin
in reducing cardiovascular mortality. Canagliflozin also re-
duced cardiovascular mortality compared with placebo. No
other head-to-head comparison of any pair of treatments (in-
cluding non-SGLT2 treatments) found a significant difference
between agents, though again for most of these comparisons,
the 95%CI was wide. SUCRAvalues are presented in Table 2.
The graphical display of the ranking based on the SUCRA
values is shown in eFig. 6. The inconsistency within the re-
spective closed loops for each comparison was overall low
(eFig. 7) and again did not reach statistical significance for
any of the loops.
Worsening HF
The predictive interval plot (Fig. 4) showed that
canagliflozin, dapagliflozin and empagliflozin all reduced
the endpoint of worsening HF when compared with pla-
cebo. There were no further significant differences in HF
outcomes between individual SGLT2i. SUCRA values are
presented in Table 2. The graphical display of the ranking
based on the SUCRA values is shown in eFig. 8. No
closed loops were formed and consequently no inconsis-
tency could be derived.
Sensitivity analyses
Sensitivity analyses essentially confirmed our main results.
When we included the results of study extension periods to
the outcome analyses, empagliflozin was again more effective
in reducing all-cause and cardiovascular mortality than all
other agents, while there was no difference between the indi-
vidual SGLT2i in reducing worsening HF (eFig. 9, 10 and 11).
Results were similar after excluding trials with a treatment
duration < 52 weeks (eFig. 12, 13 and 14) or when restricting
our analyses to patients included in cardiovascular outcome
trials (n = 38,719; eFig. 15, 16 and 17). As we did not identify
any trials with a high risk of bias, the corresponding sensitivity
analysis was not appropriate.
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Discussion
SGLT2i belong to a new class of OAD that confer benefits on
cardiovascular endpoints in patients with T2D. To date, there
is no randomised controlled trial (RCT) or retrospective head-
to-head comparison of any available SGLT2i. NMA is an
increasingly popular tool for comparative effectiveness re-
search. The integration of direct (head-to-head) and indirect
(transitively derived via a common comparator) evidence al-
lows for comparisons that otherwise elude conventional
(aggregate) analysis while increasing precision in the esti-
mates along the way. The present analysis is thus the first to
provide evidence of the comparative cardiovascular effects of
different SGLT2i in patients with T2D.
In a comprehensive analysis of almost 75,000 patients de-
rived from 64 trials, we found that while empagliflozin,
canagliflozin and dapagliflozin reduce all-cause mortality
compared with placebo, empagliflozin appears more effective
than the latter two. These results were essentially mirrored for
cardiovascular mortality, while all three appear of similar ef-
ficacy with respect to worsening HF. Ertugliflozin had no
effect on any of the three endpoints investigated.
The mortality advantage of empagliflozin reflects the re-
sults of four recently published large-scale placebo-controlled
Fig. 2 Predictive interval plot for
all-cause mortality. Legend: The
predictive interval plot represents
a forest plot of the joint estimated
summary effects from both direct
and indirect comparisons along
with their confidence intervals.
Significant results are shown in
read colour
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cardiovascular outcome trials, since these trials contribute
more than 90% of mortality events to the present analysis. In
the EMPA-REG-OUTCOME trial, empagliflozin significant-
ly reduced all-cause and cardiovascular mortality in 7020
Table 2 Surface under the
cumulative ranking curve
(SUCRA) values for all endpoints
SUCRA All-cause mortality Cardiovascular mortality Worsening HF
Canagliflozin 0.519 0.533 0.754
Dapagliflozin 0.437 0.414 0.537
Empagliflozin 0.684 0.697 0.677
Ertugliflozin 0.385 0.659 n.a.
Placebo 0.335 0.374 0.285
HF, heart failure; n.a., not available. SUCRA is a transformation of the mean rank that accounts both for the
location and the variance of all relative treatment effects. SUCRAwould be 1 when a treatment is certain to be the
best and 0 when a treatment is certain to be the worst [19]
Fig. 3 Predictive interval plot for
cardiovascular mortality. Legend:
The predictive interval plot
represents a forest plot of the joint
estimated summary effects from
both direct and indirect
comparisons along with their
confidence intervals. Significant
results are shown in red colour
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patients with T2D at high cardiovascular risk [6]. In contrast,
dapagliflozin had a neutral effect on survival in 17,160 pa-
tients included in the DECLARE-TIMI 58 trial [5].
Similarly, canagliflozin did not affect overall survival or car-
diovascular death both in 10,142 patients enrolled in the
CANVAS programme and in 4401 patients enrolled in the
CREDENCE trial [4, 61], though in all cases, the 95% CI of
the effect measure just touched the null-effect line.
Our findings may reflect features of trial designs or actual
differences between the agents. Although molecules of
dapagliflozin and canagliflozin are very similar to those of
empagliflozin, small differences in the molecular structure
can potentially lead to critical differences. For example, the
molecular differences between the hormones testosterone and
estradiol are substantially smaller than the differences between
the empagliflozin molecule and the other two members of the
class [88]. However, individual SGLT2i share their mode of
action as well as important pharmacological characteristics
including bioavailability, receptor selectivity, metabolism,
elimination half-life and excretion [89, 90]. In addition, they
have comparable effects on blood glucose, body weight and
blood pressure, which are the suggested mediators of the anti-
atherosclerotic effects of SGLT2i.
The difference in survival benefit between individual
SGLT2i may potentially be explained by differences in trial
populations. For example, the number of patients with
established atherosclerotic cardiovascular disease in EMPA-
REG-OUTCOME was significantly higher than in the other
trials. The mortality rate in the placebo group of the EMPA-
REG-OUTCOME trial was higher than in the other SGLT2i
cardiovascular outcome trials, highlighting the differences be-
tween populations. An additional factor is that the number of
patients with concomitant chronic kidney disease varied be-
tween trials. As patients with impaired renal function may
gain a greater benefit from SGLT2i therapy, exclusion of these
patients from the DECLARE-TIMI 58 trial may have limited
mortality benefits [91].
To date, data on the cardiovascular effects of ertugliflozin
are scarce. The present NMA includes seven trials totalling
4740 patients treated with ertugliflozin; however, these trials
reported only 17 deaths. Due to the low number of events,
mortality analyses result in wide confidence intervals and
should therefore be interpreted with caution. The cardiovas-
cular efficacy and safety of ertugliflozin in patients with T2D
is currently being evaluated in the VERTIS-CV trial. The trial
completed enrolment in 2017 and the results are expected to
be published in 2020 [92].
The present NMA shows a clear reduction in HF events
with canagliflozin, dapagliflozin and empagliflozin, with no
significant difference between individual SGLT2i. Again,
these results are mainly driven by the four large-scale cardio-
vascular outcome trials, which reported a relative 30–40% risk
reduction for worsening HF for each agent [4–6, 61]. Notably,
the benefit was independent of baseline cardiovascular risk or
a history of HF [93–95]. The benefits with SGLT2i for HF
outcomes may be secondary to a reduction in circulating vol-
ume and other haemodynamic effects with a reduction of
myocardial loading [93–95]. Natriuresis [96], systemic blood
pressure lowering [97], modification of the intrarenal renin
angiotensin axis [98] and reduction in arterial stiffness [99]
Fig. 4 Predictive interval plot for
worsening HF. Legend: The
predictive interval plot represents
a forest plot of the joint estimated
summary effects from both direct
and indirect comparisons along
with their confidence intervals.
Significant results are shown in
red colour
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may all contribute to the protection afforded [94]. These ef-
fects have been reported for all the different SGLT2i, consis-
tent with the comparable HF efficacy of individual SGLT2i.
In the present NMA, no significant differences in mortality
or HF efficacy were found when comparing individual
SGLT2i to other active treatments. This contrasts to two re-
cently published meta-analyses in which the use of SGLT2
inhibitors was associated with lower mortality and a lower
risk of HF compared with dipeptidyl peptidase 4 inhibitors
[100, 101]. The meta-analyses, however, compared classes
of drugs, whereas the present NMA presents comparisons of
individual agents. As the number of events included in each
analysis is low, comparisons of individual SGLT2i with other
active treatments need to be interpreted with caution.
Limitations
The present NMA includes all the available evidence regard-
ing the effects of SGLT2i on commonly accepted endpoints in
patients with T2D. It deliberately excludes the recently pub-
lished DAPA-HF trial [102]. This is because all trials (except
DAPA-HF) included T2D patients—of whom some had
chronic HF—while DAPA-HF included only chronic HF
patients—of whom some had T2D. This would substantially
skew baseline characteristics between DAPA-HF and all other
studies. The ensuing violation of the transitivity assumption
would thus invalidate the entire NMA. Several other potential
study limitations should be considered.
First, most trials in the present NMA included a relatively
small number of patients, with four trials contributing almost
half of the study population.
Second, the mean follow-up duration of the core trials was
40 weeks, which limits mortality analyses. However, our re-
sults were confirmed in a sensitivity analysis restricted to trials
with a treatment duration of at least 52 weeks.
Third, the majority of studies included were not designed
as cardiovascular outcome trials. They were therefore not
powered to detect differences in survival between active treat-
ments and comparators. However, aggregation of individual
trial data in a (network) meta-analysis is an appropriate tool to
increase the power and validity of individual study results. In
addition, we confirmed the results of our NMA in a sensitivity
analysis that excluded non-cardiovascular outcome trials.
Fourth, baseline cardiovascular risk—if reported at all—
varied substantially between trials, with a significantly higher
number of patients with established atherosclerotic cardiovas-
cular disease included in empagliflozin trials. As patients at
high cardiovascular risk may gain a greater benefit from
SGLT2i therapy, differences between trial populations may
have biased the results. In addition, differences in background
anti-diabetic and/or cardiovascular treatment may have affect-
ed the number of cardiovascular endpoints.
Fifth, statistically significant results from a (network) meta-
analysis do not necessarily imply clinically meaningful differ-
ences in efficacy. The findings of the present study should
therefore be interpreted cautiously.
Conclusion
We found similar reductions in worsening HF with
empagliflozin, canagliflozin and dapagliflozin. However,
empagliflozin was associated with a greater reduction in all-
cause and cardiovascular mortality. Due to the low number of
events reported from ertugliflozin trials, no reliable conclusions
on cardiovascular outcomes may be drawn from ertugliflozin
analyses. Although the differences in the efficacy of individual
SGLT2imight reflect different trial designs, cliniciansmay prefer
empagliflozin over other SGLT2i until more evidence on the
comparative efficacy of SGLT2i is available.
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